Remote Head of AI-Driven Clinical Data Science

i‑Pharm Consulting; United States; Teletrabalho; USD 290 000 - 375 000; Tempo integral

Vantagens oferecidas por esta oferta de emprego

Bonus 25%

Long term incentives

Resumo da oferta

i‑Pharm Consulting seeks an Executive Director, Clinical Biometrics & Data Science [AI‑Enabled Clinical Development] to lead the next generation strategy across a global clinical pipeline, shaping how AI and advanced analytics transform clinical evidence generation. Join a research‑driven, globally distributed team blending biostatistics with machine learning to accelerate development.

The role offers remote flexibility, senior leadership exposure, and the chance to influence regulatory

Qualificações

• 10+ years in Clinical Development, Biostatistics, and Data Science.
• Experience applying AI/ML to clinical evidence generation.
• Experience influencing regulatory authorities.
• Senior leadership capable of guiding Directors and cross-functional teams.
• Background in neurology or complex biomarker domains preferred.

Responsabilidades

• Lead Clinical Data Science strategy across a multi-program global portfolio.
• Drive AI/ML integration in disease modeling, imaging, biomarkers.
• Represent Data Science in regulatory meetings and Health Authority responses.
• Shape trial design and endpoints with Biostatistics and Clinical Development.
• Mentor a geographically distributed team.
• Drive vendor, budget, and GxP-aligned analytics excellence.

Conhecimentos

Leadership

AI/ML in clinical

Biostatistics

Data Science

Regulatory liaison

Descrição da oferta de emprego

i‑Pharm Consulting seeks an Executive Director, Clinical Biometrics & Data Science [AI‑Enabled Clinical Development] to lead the next generation strategy across a global clinical pipeline, shaping how AI and advanced analytics transform clinical evidence generation. Join a research‑driven, globally distributed team blending biostatistics with machine learning to accelerate development.

The role offers remote flexibility, senior leadership exposure, and the chance to influence regulatory